(Total Views: 599)
Posted On: 10/06/2021 7:25:16 AM
Post# of 155732
This statement by Dr Recknor is very bothersome:
50. This means that the studies will experience a gap in monitoring and may not be useable for FDA approval.
I can't imagine what that would do to future investors interest in putting money at risk.
The Brazil trials must be positive.
50. This means that the studies will experience a gap in monitoring and may not be useable for FDA approval.
I can't imagine what that would do to future investors interest in putting money at risk.
The Brazil trials must be positive.
(3)
(3)
